Novavax(NVAX) ZACKS·2025-02-10 23:46Company Performance - Novavax (NVAX) closed at 0.67, indicating a 53.47% increase from the same quarter last year [2] - Revenue is forecasted to be $90.72 million, representing a 68.86% decline compared to the same quarter of the previous year [2] Analyst Estimates - Recent changes to analyst estimates for Novavax indicate a dynamic business outlook, with positive revisions suggesting optimism about the company's future performance [3] - The Zacks Rank system, which incorporates estimate changes, currently ranks Novavax at 2 (Buy) [5] Valuation Metrics - Novavax has a Forward P/E ratio of 1897.01, significantly higher than the industry's average Forward P/E of 22.99, indicating a premium valuation [6] - The company also has a PEG ratio of 61.99, compared to the Medical - Biomedical and Genetics industry's average PEG ratio of 1.51 [7] Industry Context - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 68, placing it in the top 28% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]